In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

King to sell Pain Therapeutics' abuse-resistant oxycodone; terminated

Executive Summary

Specialty pharma company King Pharmaceuticals paid $150mm in cash up front to Pain Therapeutics (PT) for a worldwide license (outside of Australia and New Zealand) to Remoxy, PT's abuse-resistant, long-acting oxycodone in Phase II trials for moderate-to-severe chronic pain. The companies also agreed to co-develop other abuse-resistant opioids including hydrocodone, hydromorphone (PTI202), and oxymorphone, all at the preclinical stage.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register